Top 25 Companies in Global Acute Agitation and Aggression Treatment Market (2025–2035): Competitive Analysis & Forecast
RELEASE DATE: Mar 2026 Author: Spherical InsightsRequest Free Sample Speak to Analyst
Description
According to a research report published by Spherical Insights & Consulting, the Global Acute Agitation and Aggression Treatment Market Size is projected to grow from USD 6.22 Billion in 2024 to USD 13.04 Billion by 2035, at a CAGR of 6.95% during the forecast period 2025–2035. The Global Acute Agitation and Aggression Treatment Market is driven by rising renewable energy demand, government incentives, declining costs, technological advancements, and increasing adoption in residential, commercial, and off-grid applications worldwide.
Introduction
The acute agitation and aggression treatment market refers to therapies and medications used to rapidly manage severe agitation or aggressive behavior associated with psychiatric and neurological disorders such as schizophrenia, bipolar disorder, dementia, and substance abuse. Market growth is driven by the rising prevalence of mental health disorders, increasing psychiatric emergency visits, and demand for fast-acting therapies such as injectable antipsychotics and benzodiazepines. Expanding healthcare infrastructure and growing awareness of mental health are further supporting adoption. Opportunities exist in innovative drug delivery systems and digital monitoring solutions. Recent developments include new therapies like sublingual dexmedetomidine (IGALMI) and ongoing clinical trials for advanced agitation treatments.
Navigate Future Markets with Confidence: Insights from Spherical Insights LLP
The insights presented in this blog are derived from comprehensive market research conducted by Spherical Insights LLP, a trusted advisory partner to leading global enterprises. Backed by in-depth data analysis, expert forecasting, and industry-specific intelligence, our reports empower decision-makers to identify strategic growth opportunities in fast-evolving sectors. Clients seeking detailed market segmentation, competitive landscapes, regional outlooks, and future investment trends will find immense value in the full report. By leveraging our research, businesses can make informed decisions, gain a competitive edge, and stay ahead in the transition toward sustainable and profitable solutions.
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Acute Agitation and Aggression Treatment Market.
Acute Agitation and Aggression Treatment Market Size & Statistics
- The Market Size for Acute Agitation and Aggression Treatment Was Estimated to be worth USD 6.22 Billion in 2024.
- The Market is Going to Expand at a CAGR of 6.95% between 2025 and 2035.
- The Global Acute Agitation and Aggression Treatment Market Size is anticipated to reach USD 13.04 Billion by 2035.
- North America is expected to generate the highest demand during the forecast period in the Acute Agitation and Aggression Treatment Market
- Asia Pacific is expected to grow the fastest during the forecast period in the Acute Agitation and Aggression Treatment Market.
Regional Growth and Demand
Asia Pacific is expected to grow the fastest during the forecast period in the Acute Agitation and Aggression Treatment market. Asia Pacific is expected to grow fastest due to rising mental health awareness, increasing psychiatric disorder prevalence, expanding healthcare infrastructure, and improving access to advanced psychiatric treatments.
North America is expected to generate the highest demand during the forecast period in the Acute Agitation and Aggression Treatment market. North America is expected to generate the highest demand due to high mental health disorder prevalence, strong healthcare infrastructure, advanced treatment availability, increased emergency psychiatric care, and significant investment in mental health research and drug development.
Top 10 Trends in the Acute Agitation and Aggression Treatment Market
- Development of rapid-acting therapies
- Shift toward non-invasive drug delivery systems
- Rising adoption of personalized medicine approaches
- Integration of digital mental health technologies
- Increasing investment in research and drug development
- Growing focus on non-pharmacological and de-escalation techniques
- Expansion of psychiatric emergency care facilities
- Increasing prevalence of dementia-related agitation
- Integration of mental health care with primary healthcare systems
- Strategic collaborations between pharmaceutical and biotech companies
1.Development of Rapid-Acting Therapies
Pharmaceutical companies are focusing on therapies that provide quick symptom relief during psychiatric emergencies. Rapid-acting antipsychotics and sedatives help stabilize patients experiencing severe agitation or aggression in emergency settings. These treatments reduce the need for physical restraints and improve safety for both healthcare professionals and patients.
- Shift Toward Non-Invasive Drug Delivery Systems
The market is witnessing a transition from traditional intramuscular injections to non-invasive formulations such as sublingual films and intranasal sprays. These delivery systems provide faster absorption and improved patient compliance. They also reduce discomfort and enable quicker treatment during acute psychiatric episodes.
- Rising Adoption of Personalized Medicine Approaches
Healthcare providers are increasingly adopting personalized treatment strategies tailored to individual patient characteristics, genetics, and medical history. Personalized medicine improves treatment effectiveness and reduces adverse drug reactions. This trend is supported by advancements in psychiatric genetics and biomarker research.
- Integration of Digital Mental Health Technologies
Digital tools such as telehealth platforms, mobile apps, and remote monitoring systems are being integrated into agitation management. These technologies enable real-time assessment, remote consultations, and early intervention. Digital mental health solutions are improving access to psychiatric care and supporting better treatment outcomes.
- Increasing Investment in Research and Drug Development
Pharmaceutical companies and research institutions are increasing investments in developing novel therapeutics for agitation and aggression management. Ongoing clinical trials and collaborations aim to introduce safer and more effective medications, driving innovation and expanding treatment options in the market.
Empower your strategic planning:
Stay informed with the latest industry insights and market trends to identify new opportunities and drive growth in the Acute Agitation and Aggression Treatment market. To explore more in-depth trends, insights, and forecasts, please refer to our detailed report.
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Acute Agitation and Aggression Treatment Market.
Top 25 Companies Leading the Acute Agitation and Aggression Treatment Market
- Pfizer Inc.
- Johnson & Johnson
- Eli Lilly and Company
- GlaxoSmithKline plc
- Otsuka Pharmaceutical Co., Ltd.
- Lundbeck A/S
- Teva Pharmaceutical Industries Ltd.
- Novartis AG
- AbbVie Inc.
- Hoffmann-La Roche Ltd.
- Bristol-Myers Squibb
- Sanofi S.A.
- AstraZeneca plc
- Amneal Pharmaceuticals LLC
- Mylan N.V.
- Sun Pharmaceutical Industries Ltd.
- Bausch Health Companies Inc.
- Apotex Inc.
- Neurocrine Biosciences Inc.
- Alkermes plc
- Biogen Inc.
- Hikma Pharmaceuticals PLC
- Aurobindo Pharma Limited
- UCB S.A.
- Servier Laboratories
- Eli Lilly and Company
Headquarters: Indianapolis, United States
Eli Lilly and Company is a global pharmaceutical leader focused on neuroscience and psychiatric therapies. The company develops medications for schizophrenia, bipolar disorder, and agitation-related conditions. Through extensive R&D investments and innovative drug development programs, Eli Lilly continues to expand treatment options for acute agitation and aggression in clinical and hospital settings.
- Pfizer Inc.
Headquarters: New York, United States
Pfizer is one of the world’s largest biopharmaceutical companies with a strong presence in central nervous system therapies. The company develops and markets medications for psychiatric and neurological disorders, including treatments addressing agitation and behavioral disturbances. Pfizer leverages global research capabilities and partnerships to advance innovative therapies for mental health conditions.
- Johnson & Johnson
Headquarters: New Brunswick, United States
Johnson & Johnson operates through its pharmaceutical division, Janssen, which develops treatments for schizophrenia, bipolar disorder, and neurological diseases. The company focuses on long-acting antipsychotics and novel psychiatric therapies. Its strong clinical research capabilities and global distribution network make it a key contributor to the acute agitation and aggression treatment market.
- Otsuka Pharmaceutical Co., Ltd.
Headquarters: Tokyo, Japan
Otsuka Pharmaceutical specializes in central nervous system and psychiatric medicines. The company is widely known for antipsychotic drugs used in schizophrenia and bipolar disorder treatment. Through collaborations with global partners and extensive clinical trials, Otsuka develops innovative therapies addressing agitation and behavioral symptoms associated with neurological and psychiatric disorders.
- Lundbeck A/S
Headquarters: Copenhagen, Denmark
- Lundbeck A/S is a neuroscience-focused pharmaceutical company dedicated to brain disorders. Its portfolio includes therapies for depression, schizophrenia, Alzheimer’s disease, and agitation-related symptoms. Lundbeck invests heavily in neurological research and collaborates with international partners to develop advanced treatments aimed at improving outcomes for patients with psychiatric agitation conditions.
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Acute Agitation and Aggression Treatment Market.
Are you ready to discover more about the Acute Agitation and Aggression Treatment market?
The report provides an in-depth analysis of the leading companies operating in the global Acute Agitation and Aggression Treatment market. It includes a comparative assessment based on their product portfolios, business overviews, geographical footprint, strategic initiatives, market segment share, and SWOT analysis. Each company is profiled using a standardized format that includes:
Company Profiles
- Pfizer Inc.
- Business Overview
- Company Snapshot
- Products Overview
- Company Market Share Analysis
- Company Coverage Portfolio
- Financial Analysis
- Recent Developments
- Merger and Acquisitions
- SWOT Analysis
- Johnson & Johnson
- Eli Lilly and Company
- GlaxoSmithKline plc
- Otsuka Pharmaceutical Co., Ltd.
- Lundbeck A/S
- Teva Pharmaceutical Industries Ltd.
- Novartis AG
- AbbVie Inc.
Our Reports
https://www.sphericalinsights.com/reports/petroleum-resin-market
https://www.sphericalinsights.com/reports/phosphonate-market
https://www.sphericalinsights.com/reports/polyetheramine-market
Conclusion
The acute agitation and aggression treatment market is expected to grow steadily, driven by rising mental health disorders, increasing psychiatric emergency cases, and demand for rapid-acting therapies. Advancements in drug delivery systems, growing R&D investments, and expanding healthcare infrastructure are further supporting market expansion. North America leads in demand due to strong healthcare systems and research investments, while Asia Pacific is projected to grow the fastest owing to improving mental health awareness and treatment accessibility. Key pharmaceutical companies continue to drive innovation through new therapies and strategic collaborations.
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Acute Agitation and Aggression Treatment Market.
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?